Merck & Co. closed an exclusive global licensing deal with Scibrunch Therapeutics for SPR-2015, a preclinical oral KRAS G12D(on) inhibitor, with total deal value up to $2.13 billion. The arrangement includes $400 million upfront, plus additional payments tied to development, regulatory, and commercialization milestones across multiple indications. The move underscores Merck’s continued investment in direct KRAS targeting as the field matures, with big-company licensing strategies increasingly centered on early-stage China-developed assets. For Scibrunch, the partnership provides non-dilutive funding and global development resources for a candidate positioned for future translational work.